8-K
Bausch & Lomb Corp (BLCO)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
December 17, 2025
Date of Report (Date of the earliest event reported)
Bausch + Lomb Corporation
(Exact Name of Registrant as Specified in Its Charter)
| Canada | 001-41380 | 98-1613662 |
|---|---|---|
| (State or Other Jurisdiction of<br>Incorporation or Organization) | (Commission<br>File Number) | (I.R.S. Employer<br>Identification Number) |
520 Applewood Crescent
Vaughan, Ontario
Canada L4K 4B4
(Address of Principal Executive Offices) (Zip Code)
(905) 695-7700
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br>Symbol(s) | Name of each exchange<br>on which registered | |
|---|---|---|---|
| Common Shares, No Par Value | BLCO | New York Stock Exchange | Toronto Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
|---|
On December 17, 2025, Bausch + Lomb Corporation (the “Company”) announced the appointment of Eduardo C. Alfonso, MD and Steven H. Collis to its board of directors (the “Board”), effective January 1, 2026, to fill the vacancies created by the departure of Brett Icahn and Gary Hu from the Board in August 2025. The Board has determined that each of Dr. Alfonso and Mr. Collis is independent in accordance with applicable New York Stock Exchange and Toronto Stock Exchange rules and the Company’s corporate governance guidelines. Dr. Alfonso and Mr. Collis have not been appointed to serve on any committees of the Board.
Dr. Alfonso and Mr. Collis will receive compensation in accordance with the Company’s Non-Employee Directors Compensation Policy (as in effect from time to time) and have entered into the Company’s standard form of director indemnification agreement.
There are no arrangements or understandings between any of Dr. Alfonso and Mr. Collis and any other person pursuant to which any of Dr. Alfonso and Mr. Collis was selected as a director, and there are no transactions in which the Company is a party and in which any of Dr. Alfonso and Mr. Collis has a material interest subject to disclosure under Item 404(a) of Regulation S-K.
A copy of the press release announcing the appointments is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
|---|
(d) Exhibits
| Exhibit<br>No. | Description |
|---|---|
| 99.1 | Press Release, dated December 17, 2025. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL). |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BAUSCH + LOMB CORPORATION | |
|---|---|
| By: | /s/ A. Robert D. Bailey |
| Name: | A. Robert D. Bailey |
| Title: | Executive Vice President and Chief Legal Officer |
Date: December 17, 2025
EX-99.1
Exhibit 99.1
Bausch + Lomb Announces Two Board of Directors Appointments
VAUGHAN, Ontario, Dec. 17, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H. Collis have been appointed to its board of directors. The appointments are effective Jan. 1, 2026, and following changes announced in August 2025 the board will be comprised of 10 directors.
“Eddie is one of the most prominent and respected ophthalmologists in the world, and Steve delivered tremendous financial growth as the longtime CEO of a Fortune 10 company,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “With decades of hard-earned insight, they will help shape the future of Bausch + Lomb as we accelerate our strategy and pursue the significant opportunities ahead.”
About Eduardo C. Alfonso
Eduardo C. Alfonso, MD, is an ophthalmologist and internationally recognized expert in corneal and external eye diseases. He serves as director of the Bascom Palmer Eye Institute and chair of the Department of Ophthalmology at the University of Miami Miller School of Medicine and holds the Kathleen and Stanley J. Glaser Chair in Ophthalmology.
Dr. Alfonso earned his bachelor’s degree and medical degree from Yale University. He completed his ophthalmology residency at the Bascom Palmer Eye Institute, followed by advanced fellowships at Harvard Medical School in cornea, external disease and ophthalmic pathology.
He joined the Bascom Palmer faculty in 1986 and became a tenured professor in 1998. Since 2007, he has led the institute, which is consistently ranked among the top ophthalmology centers in the United States. Dr. Alfonso is known for his research and clinical expertise in corneal infections, transplants and keratoprosthesis (artificial cornea), has authored hundreds of scientific publications and has received major awards from national and international ophthalmology organizations.
About Steven H. Collis
Steven H. Collis is best known for his long leadership of Cencora, Inc., one of the world’s largest pharmaceutical distribution and health care services companies. Collis earned a Bachelor of Commerce from the University of the Witwatersrand in Johannesburg, South Africa, and joined the company that would become Cencora in the mid-1990s, helping build its specialty pharmaceuticals business and rising through senior executive roles.
He became President and CEO in 2011 and served in that role through 2024, during which time the company’s annual revenue more than tripled and its global presence expanded significantly through strategic acquisitions and partnerships. Under his leadership, the company rebranded from AmerisourceBergen to Cencora in 2023 to reflect its global reach. Collis then transitioned to Executive Chairman of the Board, continuing to influence company strategy until he stepped down in late 2025.
Collis currently serves on the board of Elevance Health, a managed health care and insurance company.
###
About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.
^©^ 2025 Bausch + Lomb.
Media Contact:
T.J. Crawford
tj.crawford@bausch.com
(908) 705-2851
Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
Page 2